GlycoVaxyn
GlycoVaxyn is a privately held, clinical-stage Swiss biotechnology company (founded 2004, Schlieren) that develops recombinant-DNA-based glycoconjugate vaccines against bacterial infections, funded through 2010 by Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity.
- Company typePrivate
- Founded2004
- HeadquartersSchlieren, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GlycoVaxyn does
GlycoVaxyn is a Swiss clinical-stage biotechnology company founded in 2004 and headquartered in Schlieren, Switzerland. According to its firmographic profile, the company develops and manufactures biological conjugate vaccines against bacterial infections using recombinant DNA technology — a glyco-conjugation approach that uses biological (rather than purely chemical) methods to attach polysaccharide antigens to carrier proteins. With 11–50 employees and a private, for-profit corporate structure, GlycoVaxyn operates as a focused specialty biotech targeting bacterial pathogens through its proprietary conjugation platform.
The company's commercial activity to date is centered on R&D pipeline advancement funded by venture capital. Between 2006 and 2010, GlycoVaxyn closed four disclosed financing rounds totaling approximately $34.3 million, with a syndicate of specialist European life-sciences investors — Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity — providing continuity across rounds. Leadership is anchored by Philippe Dro as Chief Executive Officer and board member. No product approvals, commercial launches, named pharmaceutical partners, licensing deals, or revenue figures are disclosed in the available input data, indicating the business remains in a pre-commercial development stage within the disclosed window.
Note on data integrity: the publicly accessible web property at glycovaxyn.com presents generic technology-infrastructure marketing content (server architectures, neural networks, cybersecurity services) with testimonial names drawn from fictional film characters (Sarah Connor, Marcus Wright, Miles Dyson, John Anderson) and self-reported statistics of zero projects, partners, and awards. This content is inconsistent with the firmographic vaccine-biotech profile and is not relied upon as evidence of GlycoVaxyn's products, technology, or customers.
GlycoVaxyn firmographics
Firmographics- Name
- GlycoVaxyn
- Legal name
- Glycovaxyn
- Website
- https://glycovaxyn.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GlycoVaxyn is a privately held, clinical-stage Swiss biotechnology company (founded 2004, Schlieren) that develops recombinant-DNA-based glycoconjugate vaccines against bacterial infections, funded through 2010 by Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity.
- Ownership category
- akta.pro rank
GlycoVaxyn industry classification
Industry- Product category
- Biopharmaceutical vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)
- akta.pro secondary industry
- Travel & Tropical Disease Vaccines (HLAIAEAE)
Keywords
Where GlycoVaxyn is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
GlycoVaxyn business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Technology Infrastructure Services: Providing enterprise technology infrastructure solutions including server architectures, neural network deployments, and cybersecurity services. Revenue appears to be generated through project-based engagements and ongoing service contracts for infrastructure management.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
GlycoVaxyn product offering
Product offeringCore offering
GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. Its core activity is vaccine research, development, and biological manufacturing of glycoconjugate candidates designed to prevent bacterial disease. The company operates as a small, private Swiss biopharmaceutical firm advancing its proprietary bioconjugate vaccine platform.
Product overview
GlycoVaxyn operates as a technology infrastructure company offering an integrated suite of services centered around Future Infrastructure, Neural Networks, Hardware Integration, and Cyber Security. The core offering combines advanced server architectures (Future Infrastructure) with AI-powered neural network solutions, custom hardware integration for IoT endpoints, and military-grade cybersecurity protection. These services are engineered for scalability and performance, targeting enterprise clients seeking comprehensive digital transformation solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Biological conjugation vaccines for bacterial infections Vaccines developed and manufactured using biological conjugation and recombinant DNA technology to prevent bacterial infections. Targeted at public health agencies, global health organizations, and pharmaceutical partners seeking in-licensed or co-developed vaccine candidates.
Quantifiable outcome
- 99.99% uptime for server infrastructure
- +1 more outcomes
Companies that use GlycoVaxyn
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
GlycoVaxyn technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
GlycoVaxyn partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights2 records
GlycoVaxyn competitors and assessment
Company assessmentDirect peers
- Novavax: Recombinant vaccine platform company using protein subunit / recombinant DNA technology. Compares on platform-based approach to infectious disease vaccination and capital-intensive development profile.
- Bavarian Nordic: European vaccine developer with platforms spanning viral and bacterial indications. Compares on European origin, biodefense and infectious disease focus, and clinical-stage specialty vaccine positioning.
- Emergent BioSolutions: Specialty vaccine biotech developing products against bacterial and emerging infectious threats. Comparable on niche infectious disease focus, smaller scale relative to big pharma, and platform-based pipeline approach.
- Dynavax Technologies: Vaccine technology company with proprietary adjuvant and recombinant vaccine platforms. Matches on platform-based vaccine development and target markets in infectious disease prevention.
- Valneva: European commercial-stage vaccine biotech that developed bacterial/viral travel vaccines and infectious disease products. Comparable to GlycoVaxyn in geographic roots (Switzerland/France), specialty vaccine focus, and historical Series B/C-stage profile.
Emerging players
- VBI Vaccines: Smaller-scale vaccine platform company with pipeline targeting infectious disease. Comparable as a peer-stage clinical biotech focused on specialty vaccine indications.
- Biological E: Indian vaccine manufacturer with expansive pipeline including conjugate vaccines. Compares in product category (conjugate/bacterial vaccines), though larger scale and geographic focus differ.
Broad incumbents
- GSK (Vaccines): Major global vaccine manufacturer with deep portfolio in bacterial and conjugate vaccines. Adjacent incumbent that has historically partnered with and acquired specialty vaccine biotechs of comparable size and platform type.
- Sanofi Pasteur: Global vaccines division of Sanofi and one of the largest vaccine manufacturers. Broad incumbent with overlapping bacterial and conjugate vaccine programs; comparable as a potential partner/competitor in the same product class.
- Merck & Co. (Vaccines): Leading pharmaceutical company with substantial infectious disease and bacterial vaccine franchises. Represents the scale boundary and potential acquirer profile of a successful smaller biotech platform player.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
GlycoVaxyn social profiles
Digital presenceGlycoVaxyn financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlycoVaxyn leadership team
Management profileNumber of profiles
Profiles1 record
GlycoVaxyn funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlycoVaxyn M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlycoVaxyn
What does GlycoVaxyn do?
GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. Its core activity is vaccine research, development, and biological manufacturing of glycoconjugate candidates designed to prevent bacterial disease. The company operates as a small, private Swiss biopharmaceutical firm advancing its proprietary bioconjugate vaccine platform.
Is GlycoVaxyn a public or private company?
GlycoVaxyn is a private company. It is classified as venture growth investor backed and is currently operating.
When was GlycoVaxyn founded?
GlycoVaxyn was founded in 2004. It employs 11 to 50 people.
Where is GlycoVaxyn based?
GlycoVaxyn is headquartered in Schlieren, Switzerland, in the Europe region.
How does GlycoVaxyn make money?
One revenue line is on record: technology Infrastructure Services.
Who are GlycoVaxyn's main competitors?
Direct peers on record are Novavax, Bavarian Nordic, Emergent BioSolutions, Dynavax Technologies and Valneva. Emerging players are VBI Vaccines and Biological E. Broad incumbents are GSK (Vaccines), Sanofi Pasteur and Merck & Co. (Vaccines).
Does GlycoVaxyn have an API?
No public API is recorded for GlycoVaxyn.
What industry is GlycoVaxyn in?
GlycoVaxyn's product category is Biopharmaceutical vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAIAEAE, Travel & Tropical Disease Vaccines. Its NAICS code is 325414 and its SIC code is 2836.